Laura E Baldassari MD
Neuroimmunology/Multiple Sclerosis
Clinical Team Leader, Neuroimmunology, Division of Neurology 2, Office of New Drugs
Join to View Full Profile
10903 New Hampshire AveSilver Spring, MD 20993
Dr. Baldassari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Neuroimmunology & Multiple Sclerosis, 2017 - 2019
University of Utah HealthFellowship, Neuroimmunology & Multiple Sclerosis, 2016 - 2017
Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2012 - 2016
Georgetown University School of MedicineClass of 2012
Johns Hopkins Bloomberg School of Public HealthMHS, Epidemiology, 2006 - 2008
Certifications & Licensure
UT State Medical License 2016 - 2026
MO State Medical License 2012 - 2016
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- Severe gastrointestinal adverse reactions including perforation, ulceration, hemorrhage, and obstruction: A fumaric acid ester class new safety risk.Tiffany Kim, Allen Brinker, David Croteau, Paul R Lee, Laura E Baldassari
Multiple Sclerosis. 2025-04-01 - Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.David Croteau, Tiffany Kim, Vicky Chan, Jessica Stevens, Daniela A Pimentel Maldonado
Multiple Sclerosis and Related Disorders. 2024-12-01 - 10 citationsImmune-mediated colitis associated with ocrelizumab: A new safety risk.Tiffany Kim, Allen Brinker, David Croteau, Paul R Lee, Laura E Baldassari
Multiple Sclerosis. 2023-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
